217 related articles for article (PubMed ID: 37439536)
21. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
[TBL] [Abstract][Full Text] [Related]
23. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
[TBL] [Abstract][Full Text] [Related]
24. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez Pereña A; Marcos Gonzalez S; Teran-Villagra N; Azueta A; Batlle A; Gonzalez de Villambrosia S; Revert Arce J; Montes-Moreno S
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):e68-e71. PubMed ID: 29629945
[TBL] [Abstract][Full Text] [Related]
25. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
[No Abstract] [Full Text] [Related]
26. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
27. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
[TBL] [Abstract][Full Text] [Related]
28. The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.
Montesinos-Rongen M; Terrao M; May C; Marcus K; Blümcke I; Hellmich M; Küppers R; Brunn A; Deckert M
Haematologica; 2021 Mar; 106(3):708-717. PubMed ID: 32193251
[TBL] [Abstract][Full Text] [Related]
29. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas.
Fischer L; Hummel M; Korfel A; Lenze D; Joehrens K; Thiel E
Neuro Oncol; 2011 Oct; 13(10):1090-8. PubMed ID: 21803762
[TBL] [Abstract][Full Text] [Related]
30. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
[TBL] [Abstract][Full Text] [Related]
31. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
Yuan J; Gu K; He J; Sharma S
Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
[TBL] [Abstract][Full Text] [Related]
32. Characterization of genomic alterations in primary central nervous system lymphomas.
Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling of primary vitreoretinal lymphoma.
Arai A; Takase H; Yoshimori M; Yamamoto K; Mochizuki M; Miura O
Cancer Sci; 2020 Apr; 111(4):1417-1421. PubMed ID: 32056332
[TBL] [Abstract][Full Text] [Related]
34. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
35. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.
King RL; Goodlad JR; Calaminici M; Dotlic S; Montes-Moreno S; Oschlies I; Ponzoni M; Traverse-Glehen A; Ott G; Ferry JA
Virchows Arch; 2020 May; 476(5):647-665. PubMed ID: 31863183
[TBL] [Abstract][Full Text] [Related]
36. Genomic characterization of primary central nervous system lymphoma.
Fukumura K; Kawazu M; Kojima S; Ueno T; Sai E; Soda M; Ueda H; Yasuda T; Yamaguchi H; Lee J; Shishido-Hara Y; Sasaki A; Shirahata M; Mishima K; Ichimura K; Mukasa A; Narita Y; Saito N; Aburatani H; Nishikawa R; Nagane M; Mano H
Acta Neuropathol; 2016 Jun; 131(6):865-75. PubMed ID: 26757737
[TBL] [Abstract][Full Text] [Related]
37. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
38. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
39. Whole-Exome Sequencing Revealed the Mutational Profiles of Primary Central Nervous System Lymphoma.
Zhang R; Wei B; Hu Y; Lv W; Adilai A; Yang F; Zhang J; Cheng G
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):291-302. PubMed ID: 36725383
[TBL] [Abstract][Full Text] [Related]
40. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
